10:16 ET -- Eisai Co. and Biogen Inc. are among the most talked about companies in the U.S. across all news items in the last 12 hours, according to Factiva data. A study of the companies' closely-watched lecanemab candidate for Alzheimer's disease showed the drug slowed cognitive decline by 27% compared with a placebo over 18 months but was associated with swelling and bleeding in the brain, with researchers recommending further, longer study. Dow Jones & Co. owns Factiva. (colin.kellaher@wsj.com)


(END) Dow Jones Newswires

11-30-22 1031ET